Restlessness After an Antipsychotic Change Is Not Automatically Anxiety

The Psychiatric Record | Clinical Evidence | Monday, September 14, 2026

The following scene is a fictional composite for education. No individual patient is depicted.

A patient returns after an antipsychotic dose increase. They describe feeling more anxious and spend part of the visit standing beside the chair. The medication change is documented. So is the anxiety. What remains unclear is whether the second entry has been examined in relation to the first.

There are several possible explanations. The point is to investigate the relationship before treating the symptom label as the explanation.

Akathisia belongs in that assessment. In their 2018 guideline, Pringsheim and colleagues describe both an internal experience of restlessness and observable movement. They note that the syndrome can be mistaken for anxiety or psychotic agitation, among other conditions. Early onset after starting an antipsychotic is described, but the authors also discuss persistent and withdrawal presentations.[1]

The timing can raise a question. It cannot answer it by itself.

In the fictional visit, anxious is the patient's word. It deserves to be retained, then explored. What does the patient mean by it? Is the main problem worry, a distressing need to move, or an experience they find difficult to describe? What was present before the medication change, and what is new?

Those questions are an editorial approach to clarifying the account, not a diagnostic checklist. The psychiatrist's observation and the patient's description should both remain visible. A note that records standing without asking why is incomplete in a different way from a note that records anxiety without describing what happened during the encounter.

The guideline recommends systematic assessment with a validated scale before antipsychotic treatment and during dose titration. It identifies the Barnes Akathisia Rating Scale as including observed signs, subjective awareness and distress, and a global assessment. The recommendation is designated a Good Practice Point.[1]

A baseline gives the follow-up conversation something specific to compare. It also helps keep a general impression from replacing the details that made the change noticeable.

This problem belongs in outpatient depression care as well as psychosis care. The ABILIFY tablet prescribing information lists akathisia among common adverse reactions in adult trials of adjunctive treatment for major depressive disorder. Restlessness and insomnia are also listed. The cited label is revised January 2025 and hosted by DailyMed.[2]

That is a reason to consider an adverse effect when the clinical circumstances fit. It is not evidence that a particular patient's restlessness has that cause, and it does not provide a rate for every antipsychotic or every treatment setting.

An indication explains why a medication was considered. It does not explain every symptom that appears afterward. The same discipline applies in the other direction: noticing a possible adverse effect should not erase the condition the medication was intended to treat.

The decision needs room for both problems.

Pringsheim and colleagues recommend individualizing management. Their discussion of dose reduction explicitly includes the possibility of psychiatric deterioration.[1] This is not a standing instruction to lower or stop treatment whenever someone looks restless.

In the fictional encounter, the immediate intellectual task is modest but consequential: decide what information is missing before interpreting more distress as a reason for more of the same treatment.

That might mean returning to the sequence of events, comparing today's account with the baseline, or making the observed movement and subjective experience explicit in the assessment. The aim is to identify the question the next action is meant to address.

This article does not rank treatments for akathisia or supply an add-on medication regimen. Its clinical distinction comes earlier. Restlessness after a medication change deserves an explanation that considers the treatment history, rather than one that begins and ends with the word anxiety.

Educational Disclaimer: This article provides general professional education, not individualized medical advice, a diagnosis, or a medication regimen. Assessment and treatment require clinical judgment about the individual patient. Patients should discuss new or worsening symptoms with their treating clinician and should not change medication on the basis of this article.